KUALA LUMPUR: Hextar Healthcare Bhd's net loss for the third quarter ended Sept 30, 2025 (Q3 FY25) widened to RM5.81 million from RM4.06 million a year ago.

In a filing to Bursa Malaysia today, the group attributed the loss to higher production costs and lower plant capacity utilisation during the quarter compared with the same period last year.

Revenue for the quarter, however, rose 17.5 per cent to RM35.74 million from RM30.43 million previously.

Loss per share increased to 0.53 sen from 0.40 sen in Q3 FY24.

For the first nine months of the year, the group's net loss widened to RM13.57 million from RM5.93 million a year ago, while revenue rose to RM112.58 million from RM105.3 million previously.

The group noted that the net loss for the period increased due to lower capacity utilisation of its plants compared with the first nine months of 2024.

On prospects, Hextar Healthcare foresees the overall performance of the glove division to remain challenging in the short to medium term, amidst global trade uncertainties, foreign exchange risks and rising material prices, energy and labour costs.

The group said its property investment division, which is expected to commence operations by Q4 FY25, would not have a material impact on the group's earnings.

As for the medical device operation, the group remains focused on the manufacture.

and sales of diagnostic test kits for the detection of various infectious diseases such as filariasis, malaria, typhoid, HIV and other drug-of-abuse test kits, which are distributed in Malaysia and overseas.